摘要
目的:观察吉非替尼治疗非小细胞肺癌(NSCLC)中优势人群的情况,以同期、同样治疗的NSCLC非优势人群作为对照,比较两组治疗的有效性和安全性。方法:全组共有NSCLC患者73例,均经病理组织学或细胞学检查确诊,其中33例完全符合优势人群的标准,即东方人种、女性、腺癌和非吸烟者;另外40例不符合者作为非优势人群,既往化疗效果差,均自愿接受吉非替尼单药250 mg／d治疗。结果:33例优势人群接受吉非替尼治疗后PR 15例,SD 14例,PD 4例,有效率为45．4％(15／33),DCR 87．8％(29／33),中位疾病进展时间(TTP)7个月,治疗后中位生存期9个月;而40例非优势人群治疗后PR 9例,SD 21例,PD 10例,有效率22．5％(9／40),DCR 75．0％(30／40),中位TTP 5个月,治疗后中位生存期7个月。全组患者中,腺癌和非腺癌的有效率分别为38．3％(23／60)和7．7％(1／13)。两组毒副反应一致。结论:对于NSCLC国人患者,认真挑选优势人群,合理而有计划地应用分子靶向治疗药物吉非替尼,疗效较高,可能有助于提高临床个体化治疗水平。
OBJECTIVE： To explore the efficacy and toxicity of Gefitinib （Iressa） in the treatment of dominant crowd with non-small cell lung cancer （NSCLC）. METHODS： Seventy-three Chinese patients of NSCLC with histologically or cytologically confirmed diagnosis treated with Iressa 250 mg/d. Among them, 33 patients with NSCLC meet with the dominant crowd criteria： East-Asianese, female, adenocarcinoma and non-smoking. RESULTS： Within the 33 patients with dominant crowd, there were 15 patients with PR, 14 patients with SD and only 4 patients with PD. The overall response rate and the disease control rate were 45.4% （15/33） and 87. 8% （29/33） respectively. The median time of tumor progression （TTP） was 7 months and the median time of survival （MST） after treatment was 9 months. The other 40 patients with non-dominant crowd, there were 9 patients with PR, 21 patients with SD and 10 patients with PD. The overall response rate and the disease control rate were 22.5%（9/40） and 75.0% （30/40） respectively. The median TTP was 5 months and the MST was 7 months. The response rates in adenocarcinoma and non-adenocarcinoma were 38. 3% （23/60） and 7. 7% （1/13） respectively. CONCLUSIONS： Rational selection of dominant crowd and well-planned treatment with molecular targeted drugs. That can be helpful to enhance comprehensive therapy in NSCLC.
出处
《中华肿瘤防治杂志》
CAS
2006年第24期1882-1884,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺/药物疗法
抗肿瘤药/治疗应用
喹唑啉类/治疗应用
carcinoma, non-small cell lung/drug therapy
antineoplastic agents/therapeutic uses
quinazolines/therapeutic uses
